Pew Urges Congress to Pass Medical Device User Fee Act and Improve Marketplace Monitoring
WASHINGTON – The U.S. House Energy and Commerce subcommittee on health today held a hearing on the reauthorization of the Medical Device User Fee Act (MDUFA), which allows the U.S. Food and Drug Administration (FDA) to collect fees from medical device companies and use them to review and evaluate new devices in a timely fashion. Allan Coukell, director of medical programs at the Pew Health Group, issued the following statement about the hearing:
"We applaud the FDA and the medical device industry for reaching an agreement that will spur the innovation of new therapies for improving health and saving lives. We urge Congress to include MDUFA in this year’s user-fee reauthorization package.
"In addition, as part of MDUFA, Congress can streamline the process for reviewing innovative low- and moderate-risk devices. Reforms in this area would benefit both manufacturers and patients.
"Congress also can strengthen FDA’s ability to ensure that devices on in the marketplace meet appropriate safety standards, per the recommendation of the Institute of Medicine. Many medical devices go to market without the clinical data that would allow us to confidently gauge their safety and effectiveness. As a result, we need to improve our monitoring system to ensure we catch emerging problems before they become widespread."
# # #
Pew Health Group
The Pew Health Group is the health and consumer-product safety arm of The Pew Charitable Trusts, a nonprofit organization that applies a rigorous, analytical approach to improve public policy, inform the public and stimulate civic life. www.pewtrusts.org/health.
On Thursday, May 23, the House Energy & Commerce Subcommittee on Health held a hearing, entitled "Examining Drug Compounding." Gabrielle Cosel, a drug safety expert, testified on the need to clarify oversight of compounding pharmacies on the state and federal level.
Public health and consumer advocacy groups are attacking Senate legislation designed to tighten oversight of specialized pharmacies such as the one at the center of this past fall’s deadly meningitis outbreak, saying it does not adequately address health risks. More info
An Ohio legislator’s plan to establish a nationwide prescription drug tracking system to protect patients from fake drugs was approved by the House Commerce Committee. More info